GlassScriptPhysician profile
Jarred T Burkart
NPI 1205102001
$4,045.04
in general payments reported to CMS, 2019-2025
14 companies · $3,238 in 2025
The $3,238 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.92 · 2021: $11.92 · 2022: $106 · 2023: $323 · 2024: $349 · 2025: $3,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,709 · Food and Beverage: $1,116 · Education: $86.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,708.50 |
| Food and Beverage | $1,115.63 |
| Education | $86.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,941.40 | 2025 | Enhertu |
| Geron Corporation | $780.00 | 2025 | Rytelo |
| Tempus Ai, INC | $202.21 | 2024-2025 | Xt Cdx |
| Kite Pharma, INC. | $193.85 | 2022-2025 | Yescarta |
| Genentech USA, INC. | $170.67 | 2023-2025 | Lunsumio |
| Adaptive Biotechnologies Corporation | $159.64 | 2024 | Clonoseq |
| Janssen Biotech, INC. | $125.00 | 2023 | Tecvayli |
| Eisai INC. | $122.65 | 2025 | |
| Amgen INC. | $111.74 | 2024 | |
| Glaxosmithkline, LLC. | $108.38 | 2025 | Ojjaara |
| Cti Biopharma Corp. | $81.15 | 2023 | Vonjo |
| Janssen Pharmaceuticals, INC | $20.51 | 2025 | |
| Mckesson Specialty Care Distribution, LLC | $15.92 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jarred Burkart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.